Methotrexat Ebewe (Methotrexate)

Methotrexate blocks dihydrofolate reductase, an enzyme needed to regenerate tetrahydrofolate. This limits the synthesis of purines and pyrimidines, which are essential building blocks for DNA and RNA. The result is reduced proliferation of rapidly dividing cells such as immune cells, cancer cells and trophoblastic tissue.

The specific dose of Methotrexat Ebewe is determined by the prescribing clinician based on the patient’s diagnosis, disease severity, renal and hepatic function, and other individual factors. Only a qualified health‑care professional should set the dosing regimen.

Methotrexat Ebewe is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal harm. It is also not recommended during breastfeeding, as methotrexate can be excreted in milk and may affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Methotrexate is a conventional disease‑modifying antirheumatic drug (DMARD) and antimetabolite, often used before or alongside biologic agents such as TNF inhibitors. Compared with newer biologics, methotrexate is less expensive and administered orally, but it may require more laboratory monitoring for toxicity.

Methotrexat Ebewe should be stored at temperatures below 25 °C in its original container, protected from moisture and direct sunlight. Keep the product out of reach of children and do not use it after the expiration date printed on the label.

Methotrexat Ebewe is supplied as an oral formulation. It is taken by mouth with or without food according to the prescriber’s instructions. Some regimens may include folic acid supplementation to reduce certain side effects, but this should be directed by a health‑care professional.

The most serious adverse events include severe liver toxicity (hepatitis, fibrosis), bone‑marrow suppression leading to pancytopenia, and pulmonary complications such as interstitial pneumonitis or fibrosis. Early detection through regular laboratory monitoring is essential to mitigate these risks.

Methotrexat Ebewe should be avoided in pregnant or nursing women, patients with severe hepatic impairment, uncontrolled infections, known hypersensitivity to methotrexate, and individuals with significant renal dysfunction unless dose adjustments are made under medical supervision.